Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 9/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 4/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.56 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9137670 | 1.00 | PLA2G2A (0.56) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL8917115 | 1.00 | PLA2G2A (0.56) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL8979451 | 0.99 | PLA2G2A (0.54) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL8357825 | 0.96 | PLA2G2A (0.59) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL8974114 | 0.93 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL8004697 | 0.93 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL8004701 | 0.93 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL2233038 | 0.91 | PLA2G2A (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL704578 | 0.91 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 | |
| SCHEMBL2234605 | 0.91 | PLA2G2A (0.49) | PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106032-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080293667-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2008-11-27 | — | — | US | disclosed |
| EP-0781138-B1 | LIPID ANALOGS FOR TREATING VIRAL INFECTIONS | UNIV WAKE FOREST (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7294621-B2 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294620-B2 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294619-B2 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1852121-A2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20070105811-A1 | Lipid analogs for inhibiting the activity of hepatitis B antigen | WAKE FOREST UNIVERSITY | 2007-05-10 | — | — | US | disclosed |
| US-20070099870-A1 | Lipid analogs for combating tumors | WAKE FOREST UNIVERSITY | 2007-05-03 | — | — | US | disclosed |
| US-7135584-B2 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7129227-B1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050080050-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040259845-A1 | Lipid analogs for treating viral infections | WAKE FOREST UNIVERSITY | 2004-12-23 | — | — | US | disclosed |
| EP-0702556-B1 | (PHOSPHO)LIPIDS FOR COMBATTING HEPATITIS B VIRUS INFECTION | UNIV WAKE FOREST (US) | 2002-10-23 | — | — | EP | disclosed |
| US-6030960-A | INHIBITING THE PRODUCTION OF HEPATITIS VIRUS-INDUCED ANTIGENS IN A HUMAN SUBJECT BY ADMINISTERING A COMPOUND | WAKE FOREST UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5962437-A | HEPATITIS, HERPES AND AIDA VIRUS | WAKE FOREST UNIVERSITY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5770584-A | ADMINISTERING AN ALKYL LIPID OR ALKYL LIPID DERIVATIVE VIRICIDES | WAKE FOREST UNIVERSITY (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0702556-A1 | (PHOSPHO)LIPIDS FOR COMBATTING HEPATITIS B VIRUS INFECTION | WAKE FOREST UNIVERSITY (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994028908-A2 | (PHOSPHO)LIPIDS FOR COMBATTING HEPATITIS B VIRUS INFECTION | WAKE FOREST UNIVERSITY (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105812-A1 | Lipid analogs for inhibiting HIV-1 activity | SGMS1, HDLBP, LIPC | PLA2G2A 107/4885PLA2G10 232/4885PLA2G1B 86/4885 |
| US-20070105811-A1 | Lipid analogs for inhibiting the activity of hepatitis B antigen | LIPC, APOB, PNLIP | PLA2G2A 34/4885PLA2G10 92/4885PLA2G1B 42/4885 |
| US-20040259845-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | PLA2G2A 133/4885PLA2G10 270/4885PLA2G1B 130/4885 |
| US-20050080050-A1 | Lipid analogs for treating viral infections | SGMS1, PHOSPHO1, SGMS2 | PLA2G2A 133/4885PLA2G10 270/4885PLA2G1B 130/4885 |
| US-20080293667-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | PLA2G2A 41/4885PLA2G10 133/4885PLA2G1B 50/4885 |
| US-20070099870-A1 | Lipid analogs for combating tumors | SGMS1, PNLIP, SGMS2 | PLA2G2A 41/4885PLA2G10 133/4885PLA2G1B 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.